# A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT03646071** · PHASE1 · UNKNOWN · sponsor: **NeuPharma, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Locally Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** RX108

## Key facts

- **NCT ID:** NCT03646071
- **Lead sponsor:** NeuPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2023-08
- **Final completion:** 2023-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03646071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03646071, "A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03646071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*